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Editorial
WORLD KIDNEY DAY, MARCH 11, 2010: WE 
MUST ACT ON DIABETIC KIDNEY DISEASE
In 2003, the International Society of Nephrology (ISN) 
and the International Diabetes Federation (IDF) 
launched a booklet called Diabetes and Kidney Disease: 
Time to Act [1] to highlight the global pandemic of type 
2 diabetes and diabetic kidney disease. It aimed to alert 
governments, health care organizations and providers, 
doctors and patients to the increasing health and socio-
economic problems due to diabetic kidney disease and 
its sequelae, end-stage kidney disease requiring dialysis 
and cardiovascular death. Seven years later, the same 
message has become even more urgent. World Kidney 
Day 2010, under the auspices of the ISN and the Inter-
national Federation of Kidney Foundations (IFKF), 
together with the IDF, provides yet another chance to 
underline the importance of diabetic kidney disease, 
stress its lack of awareness at both public and govern-
ment levels, and emphasize that its management in-
volves prevention, recognition and treatment of its 
complications. Primary prevention of type 2 diabetes 
will require massive lifestyle changes in the developing 
and developed world supported by strong governmental 
commitment to promote lifestyle and societal change.
THE GLOBAL THREAT OF TYPE 2 DIABETES
The 21st century has the most diabetogenic environment 
in human history [2,3]. Over the past 25 years or so, the 
prevalence of type 2 diabetes in the USA has almost 
doubled, with three- to five-fold increases in India, 
Indonesia, China, Korea and Thailand [4]. In 2007, there 
were 246 million people with diabetes in the world, but 
by 2025, that number is estimated to reach 380 million 
[5]. People with impaired glucose tolerance, a “predia-
betic state” numbered 308 million in 2007, and will 
increase to 418 million by 2025 [5]. The increase in the 
prevalence of diabetes will be greater in developing 
countries. In Mexico for example, 18% of its adult 
population will have type 2 diabetes by 2025. Accord-
ing to the World Health Organization, China and India 
will have about 130 million diabetics by 2025, who will 
consume about 40% of their country’s health care bud-
get in addition to reducing productivity and hindering 
economic growth.
It was against this background that on December 21, 
2006, the United Nations General Assembly unani-
mously passed Resolution 61/225 declaring diabetes to 
be an international public health issue and identifying 
World Diabetes Day as a United Nations Day, only the 
second disease after HIV/AIDS to attain that status. For 
the first time, governments have acknowledged that a 
noninfectious disease poses as serious a threat to world 
health as infectious diseases like HIV/AIDS, tubercu-
losis and malaria. The problems of diabetes are now 
seen as a major global public health concern, especially 
in the developing world, which can least afford it. The 
first step for acting on diabetic kidney disease must 
encompass public health campaigns aimed at preventing 
the development of type 2 diabetes.
DIABETIC KIDNEY DISEASE
Diabetes is now the major cause of end-stage kidney 
failure throughout the world in both developed and 
emerging nations [6]. It is the primary diagnosis causing 
kidney disease in 20–40% of people starting treatment 
for end-stage renal disease worldwide [7]. In Australia, 
new type 2 diabetes patients starting dialysis increased 
five-fold between 1993 and 2007 [8]. Between 1983 
and 2005, there was a seven-fold increase in new patients 
starting renal replacement therapy in Japan because 
of diabetes, accounting for 40% of all new incidence 
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patients [9]. Thus, some 30% of the predicted 1.1 trillion 
dollar medical costs of dialysis worldwide during this 
decade will result from diabetic nephropathy [10].
In the United Kingdom Prospective Diabetes Study 
(UKPDS), the rates of progression of newly diagnosed 
type 2 diabetics between the stages of normoalbuminu-
ria, microalbuminuria, macroalbuminuria and renal 
failure were 2–3% per year [11]. Over a median of 15 
years of follow-up of 4,000 participants, almost 40% 
developed microalbuminuria [12]. In the DEMAND 
study of 32,208 people from 33 countries with known 
type 2 diabetes attending their family doctor, 39% had 
microalbuminuria and prevalence increased with age, 
duration of diabetes and presence of hypertension [13]. 
About 30% of the UKPDS cohort developed renal im-
pairment, of which almost 50% did not have preceding 
albuminuria [12]. Reduced glomerular filtration rate and 
albuminuria caused by diabetic nephropathy are inde-
pendent risk factors for cardiovascular events and death 
[14]. Therefore, a strategy to detect early diabetic kidney 
disease by screening for albuminuria as well as reduced 
glomerular filtration rate is the second step in taking 
action on diabetic kidney disease.
An added difficulty to overcome is the remarkable 
lack of awareness among patients about their condition. 
In population-based surveys, for every known diabetic 
patient, there is at least one more that is unknown [15]; 
only 8.7% of the general population was able to identify 
diabetes as a risk factor for kidney disease [16]. For 
patients with diabetic kidney disease, very few are aware 
of their condition, with some community surveys putting 
patient awareness of their disease as low as 9.4%, par-
ticularly in those with milder impairment [17]. Thus, 
public education is the third step required for acting on 
diabetic kidney disease in the community. The IFKF 
has a long-term goal for all kidney patients worldwide 
to not only be aware of their disease, but to actively 
know, for example, their blood pressure and treatment 
objectives.
MANAGEMENT OF DIABETIC KIDNEY DISEASE
There is little use in screening populations or “at risk” 
groups unless follow-up is undertaken and effective 
treatment is begun and assessed [18]. Fortunately, there 
is evidence that early therapeutic intervention in patients 
with chronic kidney disease or diabetes can delay onset 
of complications and improve outcomes. For example, 
the UKPDS [19,20], STENO-2 [21] and ADVANCE 
studies [22–24] all demonstrated that tight control of 
blood glucose level and blood pressure (and lipids in 
STENO-2) significantly reduced the incidence and 
progression of diabetic kidney disease. In people with 
type 2 diabetes, inhibition of the renin-angiotensin-
aldosterone system using an angiotensin-converting 
enzyme inhibitor or an angiotensin II receptor blocker 
decreased progression from normoalbuminuria to mi-
croalbuminuria [25], reduced progression from micro-
albuminuria to macroalbuminuria [26], and slowed the 
development of end-stage renal disease [27]. Thus, the 
use of an angiotensin-converting enzyme inhibitor or 
angiotensin II receptor blocker is now standard therapy 
for patients with diabetic nephropathy as well as for 
glucose, lipid and blood pressure control. Effective 
management using evidence-based therapies is the 
fourth step in tackling diabetic kidney disease.
The fifth step is development of new therapies. Many 
new agents are now in clinical trials to reduce renal 
damage and fibrosis, including blockade of formation 
of advanced glycation endproducts and other signaling 
pathways. Other novel agents may potentially prove to 
be effective in large randomized double-blind clinical 
trials [28].
HOW CAN WE ACT NOW?
The steps to be taken are clear: (1) prevention of type 
2 diabetes; (2) screening for early diabetic kidney dis-
ease; (3) increasing patient awareness of kidney disease; 
(4) using medications of proven strategy; and finally (5) 
researching and trialing of new therapies. The ultimate 
challenge is to get action from primary health care to 
all higher levels; from the individual patient, to those at 
risk, in various health jurisdictions, in all countries 
despite varying economic circumstances and priorities. 
The problem is a global one and yet requires action at 
a local level; preventive screening and treatment strate-
gies; education, including increasing awareness both 
in diabetic patients and those at risk of developing dia-
betes; and health priorities and governments. Basic 
research and clinical trials searching for a new under-
standing and therapies must be supported.
The United Nations, as noted earlier, recognized the 
importance of diabetes in 2006 by establishing a World 
Diabetes Day. Both the ISN and the IDF are working 
closely with the World Health Organization to provide 
increasing understanding of the challenge that diabetic 
kidney disease poses to world health and health care 
budgets. However, World Kidney Day also provides a 
focus for other international agencies, government 
ministries of health, non-governmental organizations, 
foundations and academic institutions to come together 
with national kidney foundations to be involved in the 
effort to prevent and manage diabetic kidney disease.
The ISN, through its Commission for the Global 
Advancement of Nephrology Research and Prevention 
Committee has developed the web-based KHDC 
Program (which is a program for detection and manage-
ment of chronic kidney disease, hypertension, diabetes 
and cardiovascular disease in developing countries; 
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pdf/ed_051027_2x1.pdf) as a global template. The detec-
tion, management and data assessment program has so 
far screened some 42,000 people in 25 developing 
countries. The data are being stored and analyzed at the 
Kidney Disease Data Center at the committee headquar-
ters in the Mario Negri Institute in Bergamo, Italy. This 
program can be tailored to any individual country’s needs 
and resources. The IFKF also has a program initiated 
by the National Kidney Foundation in the USA called 
the Kidney Early Evaluation Program (KEEP), which 
is a screening program for people at high risk of kidney 
disease. KEEP has now been implemented in many 
countries and is used to screen and manage patients with 
diabetic kidney disease.
The focus on diabetic kidney disease for World 
Kidney Day 2010 brings awareness of the magnitude 
of the problem and ramifications for global health for 
people with diabetes and kidney disease. It is therefore 
time to act and act urgently. It is time for strategies that 
prevent diabetes and its sequelae. It is time for programs 
that health care workers can use to diagnose and treat 
people with diabetic kidney disease. It is time for gov-
ernments to pass legislation to enable the diabetes 
pandemic to be controlled. After all, diabetic kidney 
disease, like the epidemics of infectious diseases that 
have long dominated public health agendas, is poten-
tially preventable. Indeed, March 11, 2010 is the time 
to act on diabetic kidney disease and to sustain that 
action long after World Kidney Day.
ACKNOWLEDGMENTS
The authors would like to acknowledge Dr. Anne 
Reutens’ contributions to the manuscript.
REFERENCES
1. International Diabetes Federation and International Society of 
Nephrology. Diabetes and Kidney Disease: Time to Act. Brussels: 
IDF & ISN, 2003.
2. Zimmet P, Alberti K, Shaw J. Global and societal implications of 
the diabetes epidemic. Nature 2001;414:782–7.
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: 
prevalence, numerical estimates, and projections. Diabetes Care 
1998;21:1414–31.
4. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic 
obesity and type 2 diabetes in Asia. Lancet 2006;368:1681–8.
5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose 
tolerance. In: Gan D, ed. Diabetes Atlas, 3rd edition. Brussels: 
International Diabetes Federation, 2006:15–109.
6. Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic 
kidney disease. In: Ekoé JM, Rewers M, Williams R, eds. The 
Epidemiology of Diabetes Mellitus: An International Perspective, 
2nd edition. Chichester: John Wiley & Sons, 2008:499–518.
7. National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases. International comparisons. In: 2007 
Annual Data Report: Atlas of Chronic Kidney Disease and End-
Stage Renal Disease in the United States. Bethesda: National 
Institutes of Health, National Institute of Diabetes and Digestive 
and Kidney Diseases, 2007:239–54.
8. Appendix II. In: McDonald S, Excell L, Livingston B, eds. 
ANZDATA Registry Report 2008. Adelaide, Australia: Australia and 
New Zealand Dialysis and Transplant Registry, 2008:1–97.
9. Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. 
Chronic kidney disease perspectives in Japan and the importance 
of urinalysis screening. Clin Exp Nephrol 2008;12:1–8.
10. Lysaght M. Maintenance dialysis population dynamics: current 
trends and long-term implications. J Am Soc Nephrol 2002;13 
(Suppl 1):S37–40.
11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman 
RR; UKPDS Group. Development and progression of nephropathy 
in type 2 diabetes: the United Kingdom Prospective Diabetes Study 
(UKPDS 64). Kidney Int 2003;63:225–32.
12. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS 
Study Group. Risk factors for renal dysfunction in type 2 diabetes: 
U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832–9.
13. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; 
DEMAND Investigators. Prevalence and risk factors for 
microalbuminuria in a referred cohort of type II diabetic patients: 
a global perspective. Kidney Int 2006;69:2057–63.
14. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine 
M, et al; ADVANCE Collaborative Group. Albuminuria and kidney 
function independently predict cardiovascular and renal outcomes 
in diabetes. J Am Soc Nephrol 2009;20:1813–21.
15. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron 
AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired 
glucose tolerance: the Australian Diabetes, Obesity and Lifestyle 
Study. Diabetes Care 2002;25:829–34.
16. White SL, Polkinghorne KR, Cass A, Shaw J, Atkins RC, Chadban 
SJ. Limited knowledge of kidney disease in a survey of AusDiab 
study participants. Med J Aust 2008;188:204–8.
17. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, 
McFarlane SI, Chen SC, et al; KEEP Investigators. Diabetes mellitus 
and CKD awareness: the Kidney Early Evaluation Program (KEEP) 
and National Health and Nutrition Examination Survey (NHANES). 
Am J Kidney Dis 2009;53(4 Suppl 4):S11–21.
18. Thomas MC, Viberti G, Groop PH. Screening for chronic kidney 
disease in patients with diabetes: are we missing the point? Nat Clin 
Pract Nephrol 2008;4:2–3.
19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year 
follow-up of intensive glucose control in type 2 diabetes. N Engl J 
Med 2008;359:1577–89.
20. Bilous R. Microvascular disease: what does the UKPDS tell us 
about diabetic nephropathy? Diabet Med 2008;25(Suppl 2):25–9.
21. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a 
multifactorial intervention on mortality in type 2 diabetes. N Engl 
J Med 2008;358:580–91.
22. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, 
et al; ADVANCE Collaborative Group. Effects of a fixed 
combination of perindopril and indapamide on macrovascular and 
microvascular outcomes in patients with type 2 diabetes mellitus 
(the ADVANCE trial): a randomised controlled trial. Lancet 
2007;370:829–40.
23. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, 
et al; ADVANCE Collaborative Group. Intensive blood glucose 
Hong Kong J Nephrol • April 2010 • Vol 12 • No 1 5
 Diabetic kidney disease: act now or pay later
 control and vascular outcomes in patients with type 2 diabetes. 
N Engl J Med 2008;358:2560–72.
24. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, 
et al; ADVANCE Collaborative Group. Combined effects of routine 
blood pressure lowering and intensive glucose control on 
macrovascular and microvascular outcomes in patients with type 2 
diabetes: new results from the ADVANCE trial. Diabetes Care 
2009;32:2068–74.
25. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al; 
Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) 
Investigators. Preventing microalbuminuria in type 2 diabetes. 
N Engl J Med 2004;351:1941–51.
26. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, 
Arner P; Irbesartan in Patients with Type 2 Diabetes and 
Microalbuminuria Study Group. The effect of irbesartan on the 
development of diabetic nephropathy in patients with type 2 
diabetes. N Engl J Med 2001;345:870–8.
27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, 
et al; Collaborative Study Group. Renoprotective effect of the 
angiotensin-receptor antagonist irbesartan in patients with 
nephropathy due to type 2 diabetes. N Engl J Med 2001;345:
851–60.
28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic 
nephropathy. Curr Opin Nephrol Hypertens 2009;18:107–11.
